Cargando…

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

BACKGROUND: Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Laurence C., de Kraa, Rebecca, Oommen, Joyce, Chua, Grace-Alyssa, Singh, Sajla, Hughes, Anastasia M., Ferrari, Emanuela, Ford, Jette, Chiu, Sung K., Stam, Ronald W., Kees, Ursula R., Malinge, Sébastien, Kotecha, Rishi S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082024/ https://www.ncbi.nlm.nih.gov/pubmed/33937032 http://dx.doi.org/10.3389/fonc.2021.631594

Ejemplares similares

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
por: Cheung, Laurence C., et al.
Publicado: (2022)

Characterization of mesenchymal stem cells in pre-B acute lymphoblastic leukemia
por: Hughes, Anastasia M., et al.
Publicado: (2023)

New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment
por: Cheung, Laurence C., et al.
Publicado: (2018)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution
por: Anderson, Denise, et al.
Publicado: (2020)

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma—an aggressive and fatal disease
por: Stirnweiss, Anja, et al.
Publicado: (2017)

B‐cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement
por: Kemps, Paul G., et al.
Publicado: (2020)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
por: Stutterheim, Janine, et al.
Publicado: (2021)

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
por: Marco-Ayala, Javier, et al.
Publicado: (2020)

Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements
por: Esposito, Maria Teresa, et al.
Publicado: (2022)

XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements
por: Louzada-Neto, Orlando, et al.
Publicado: (2020)

Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements
por: Wen, Jinquan, et al.
Publicado: (2022)

Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Eadie, Laura N., et al.
Publicado: (2023)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia
por: Karsa, Mawar, et al.
Publicado: (2022)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia
por: Khabirova, Eleonora, et al.
Publicado: (2022)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome
por: Laurent, Anouchka P., et al.
Publicado: (2020)

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin
por: Cruickshank, M N, et al.
Publicado: (2017)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

The Partial Duplication of the 5′ Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
por: Fukushima, Hiroko, et al.
Publicado: (2017)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
por: Bataller, Alex, et al.
Publicado: (2021)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
por: Kamens, Jennifer L., et al.
Publicado: (2023)

Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells
por: Nanya, Mai, et al.
Publicado: (2015)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021)

PAX5 alterations in an infant case of KMT2A‐rearranged leukemia with lineage switch
por: Nakajima, Koji, et al.
Publicado: (2022)

Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma
por: Au-Yeung, Rex K. H., et al.
Publicado: (2022)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6n1ibpl4i2sa340a6keqle87kn